Patent SG-11201909541W-A (SG)
Title: Chimeric antibody/t-cell receptor constructs and uses thereof
Inventor: HORAN LUCAS
IPC: A61P35/00
Filed: 2018-04-24
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT ~ill IIIIIIIIIImillIVIIIIIIIHo o Holonsuioloiniou oimIE (10) International Publication Number WO 2018/200582 Al C (51) International Patent Classification: C07K 14/725 (2006.01) C07K 16/30 (2006.01) A61K 35/17 (2015.01) CO7K 19/00 (2006.01) A61P 35/00 (2006.01) C12N 5/0783 (2010.01) (21) International Application Number: PCT/US2018/029217 (22) International Filing Date: 24 April 2018 (24.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/490,576 26 April 2017 (26.04.2017) US 62/490,578 26 April 2017 (26.04.2017) US 62/490,580 26 April 2017 (26.04.2017) US (71) Applicant: EUREKA THERAPEUTICS, INC. [US/US]; 5858 Horton Street, Suite 370, Emeryville, California 94608 (US). (72) Inventors: HORAN, Lucas; 2340 Powell Street, #156, Emeryville, California 94608 (US). XU, Yiyang; 7652 Chestnut Way, Pleasanton, California 94588 (US). YANG, Zhiyuan; 555 Pierce Street, Apt. 505, Albany, California 94706 (US). LIU, Hong; 5573 Woodview Drive, El So- brante, California 94803 (US). MORALES, Javier; 1778 Bird Avenue, San Jose, California 95125 (US). LIU, Lianx- ing; 1385 20th Avenue, Apt. 2, San Francisco, California 94122 (US). (74) Agent: QI, Yan; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, California 94304-1018 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, — (54) Title: CHIMERIC ANTIBODY/T-CELL RECEPTOR CONSTRUCTS AND USES THEREOF 3 41 , 4 k * Mutated Positions CD3z binding / residues Hetero-dimer stabilizin g interactions (57) : The present application provides chimeric antibody-TCR constructs comprising an antigen-binding module that specif- O ically binds to a target antigen and a T cell receptor module capable of recruiting at least one TCR-associated signaling molecule. Also \" provided are methods of making and using these constructs. [Continued on next page] WO 2018/200582 Al MIDEDIM011010EIRDERI001010111111111111111111111111111111111111111111 UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) — with sequence listing part of description (Rule 5.2(a))